Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1997;29:1232-1239

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elhendy, A.
Right arrow Articles by Fioretti, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elhendy, A.
Right arrow Articles by Fioretti, P. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ATROPINE
Medline Plus Health Information
*High Blood Pressure

(Hypertension. 1997;29:1232-1239.)
© 1997 American Heart Association, Inc.


Articles

Safety and Feasibility of Dobutamine-Atropine Stress Testing in Hypertensive Patients

Abdou Elhendy; Ron T. van Domburg; Jos R. T. C. Roelandt; Marcel L. Geleijnse; M. Mohsen Ibrahim; ; Paolo M. Fioretti

From the Thoraxcenter, University Hospital Rotterdam-Dijkzigt, Erasmus University, Rotterdam, Netherlands.

Abstract Dobutamine stress testing is increasingly used for the diagnosis and functional evaluation of coronary artery disease. The aim of this study was to assess the hemodynamic profile, safety, and feasibility of dobutamine stress testing in hypertensive patients. Dobutamine (up to 40 µg/kg per min-ute)–atropine (up to 1 mg) stress echocardiography was performed for the detection of myocardial ischemia in 1164 patients with limited exercise capacity (age, 60±12 years; 761 men); 446 patients were known to have hypertension. The test was considered feasible when 85% of the maximal heart rate and/or an ischemic end point (new or worsened wall motion abnormalities, ST segment depression, or angina) was achieved. No myocardial infarction or death occurred during the test. Dobutamine induced a significant increase of heart rate in patients with and without hypertension (59±25 and 63±23 beats per minute, respectively). Peak rate pressure product was similar in patients with and without hypertension (18 566±4584 and 18 230±4508). Hypotension (systolic pressure drop >40 mm Hg) during the test was more frequent in hypertensive patients (7% versus 4% in normotensive, P<.05). Independent predictors of hypotension were baseline systolic pressure greater than 140 mm Hg (odds ratio, 6.9; 95% confidence interval, 3.4 to 14), older age (odds ratio, 1.04; 95% confidence interval, 1.01 to 1.07), and medication with calcium channel blockers (odds ratio, 1.8; 95% confidence interval, 1.1 to 3.5). The prevalence of ventricular tachycardia was similar (4.1%) in both groups. Episodes of 10 beats or more (0.06% of patients) were terminated promptly by intravenous metoprolol administration. Dobutamine stress testing was considered feasible in 91% of patients with and 92% of patients without hypertension. Dobutamine-atropine stress echocardiography is a safe and feasible method for the assessment of hypertensive patients referred for evaluation of myocardial ischemia. Despite the higher prevalence of dobutamine-induced hypotension in these patients, the feasibility of the test is comparable to that in individuals without hypertension.


Key Words: dobutamine • echocardiography • safety • coronary artery disease




This article has been cited by other articles:


Home page
JNMHome page
A. Elhendy, J. J. Bax, and D. Poldermans
Dobutamine Stress Myocardial Perfusion Imaging in Coronary Artery Disease
J. Nucl. Med., December 1, 2002; 43(12): 1634 - 1646.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. Elhendy, R. T. van Domburg, J. J. Bax, R. Valkema, A. E. M. Reijs, E. P. Krenning, and J. R. T. C. Roelandt
Safety, Hemodynamic Profile, and Feasibility of Dobutamine Stress Technetium Myocardial Perfusion Single-Photon Emission CT Imaging for Evaluation of Coronary Artery Disease in the Elderly
Chest, March 1, 2000; 117(3): 649 - 656.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A Elhendy, R T van Domburg, J J Bax, D Poldermans, P R Nierop, M L Geleijnse, and J R T C Roelandt
The grade of worsening of regional function during dobutamine stress echocardiography predicts the extent of myocardial perfusion abnormalities
Heart, January 1, 2000; 83(1): 35 - 39.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A Elhendy, R T van Domburg, J J Bax, P R Nierop, M L Geleijnse, M M Ibrahim, and J R T C Roelandt
The functional significance of chronotropic incompetence during dobutamine stress test
Heart, April 1, 1999; 81(4): 398 - 403.
[Abstract] [Full Text]